Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several label-supported clinical claims are made (LAMA mechanism, COPD maintenance, once-daily nebulized administration, and warnings about urinary retention and narrow-angle glaucoma). However, multiple non-label claims are included (company development/rights/partnership) and adverse reaction details are only partially supported without explicit label backing for the specific listed side effects and serious events.
Category Scores
Accurate Statements
Yupelri (revefenacin) is a long-acting muscarinic antagonist (LAMA).
Label 12.1: Revefenacin is a long-acting muscarinic antagonist (anticholinergic).
Yupelri is used for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).
Label 1: Indicated for maintenance treatment of patients with COPD. (No explicit phrase 'airflow obstruction' in provided label excerpt.)
Yupelri is administered once daily via a nebulizer.
Label 2: Recommended dosage administered by oral inhalation once daily by nebulizer using a mouthpiece.
More serious side effects of Yupelri can include urinary retention and acute angle-closure glaucoma.
Label 5.4: Worsening of urinary retention with caution. Label 5.3: Worsening of narrow-angle glaucoma (acute symptoms).
Unsupported Statements
Theravance Biopharma developed the active pharmaceutical ingredient of Yupelri.
No company development/manufacturing details provided in the supplied label excerpts.
Dr. Reddy's Laboratories holds the commercialization rights for Yupelri in the United States.
No commercialization rights details provided in the supplied label excerpts.
Dr. Reddy's Laboratories Inc. partnered with Theravance Biopharma to launch and market Yupelri in the U.S.
No partnership/launch/marketing details provided in the supplied label excerpts.
Common side effects of Yupelri include nasopharyngitis (common cold symptoms), diarrhea, urinary tract infection, and upper respiratory tract infection.
The label excerpt provided states that Table 1 shows most common adverse reactions (>=2% and higher than placebo), but the actual listed adverse reactions are not included in the provided text, so these specific examples are not supported by the supplied excerpts.
Contradictions
Important Omissions
Dose details: 175 mcg (one 175 mcg unit-dose vial) administered by oral inhalation once daily via nebulizer using a mouthpiece; specific compressor/nebulizer systems (PARI LC Sprint with mouthpiece and PARI Trek S compressor) and that non-compressor based nebulizers have not established safety/efficacy.
Importance:
Moderate
Administration clarification: route is 'orally inhaled route via a standard jet nebulizer connected to an air compressor' (and safety/efficacy not established for non-compressor-based systems).
Importance:
Moderate
Contraindications: hypersensitivity to revefenacin or any component.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response includes some label-consistent safety warning topics (urinary retention and narrow-angle/acute glaucoma). However, it also provides specific 'common side effects' without support from the provided label excerpt and omits important dose/administration specifics (including compressor/nebulizer requirements) that could affect safe use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Unsupported non-label business/ownership claims and adverse reaction examples not supported by the provided adverse reaction excerpt.
Suggested Improvement
Limit statements to what is explicitly supported by the provided label excerpts (e.g., indication and general dosing by nebulizer once daily). Omit company development/rights/partnership claims. For adverse reactions, avoid listing specific 'common side effects' unless the label excerpt includes the actual Table 1 adverse reaction names; otherwise use only the label-supported general statement that Table 1 contains the most common adverse reactions.